EP0031 (A440/KL590586), a promising next generation selective RET inhibitor (SRI) presented at ESMO 2024

About Ellipses Pharma Limited

Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted funding flow to minimise the time it takes to advance lead products through clinical trials and reach patients.

For more information contact us: media@ellipses.life

Want to learn more?